Form 4: BioSig Technologies Director and 10% Owner Receives Significant Stock Grant Valued at $4.5 Million

Anthony N. Amato, a Director and 10% Owner of BioSig Technologies, Inc., was granted 900,000 shares of common stock valued at $5.05 per share as compensation for services.

Summary

• Anthony N. Amato, a Director and 10% Owner of BioSig Technologies, Inc. (BSGM), acquired 900,000 shares of common stock.
• The transaction occurred on May 29, 2025, and the shares were granted under the Company's 2023 Equity Incentive Plan.
• These shares were provided in lieu of cash for services rendered and were fully vested as of the grant date.
• The grant was valued based on a closing price of $5.05 per share on May 29, 2025, totaling approximately $4,545,000.
• Following this transaction, Mr. Amato directly beneficially owns 3,031,547 shares of BioSig Technologies common stock.

Sentiment

Score: 7

Explanation: The grant of a significant number of shares to a director and 10% owner is generally positive as it aligns their interests with long-term shareholder value. While it represents potential dilution, it also conserves cash for the company.

Positives

• The grant of 900,000 shares to a Director and 10% Owner significantly increases insider ownership, aligning management's interests with long-term shareholder value.
• Issuing shares in lieu of cash for services helps conserve the company's cash reserves, which can be beneficial for liquidity and operational funding.
• The immediate vesting of the shares indicates a strong commitment and immediate ownership by the insider.

Negatives

• The issuance of 900,000 shares, while a form of compensation, represents potential dilution for existing shareholders.

Risks

• Potential for future dilution from the company's 2023 Equity Incentive Plan as additional shares may be granted to other insiders or employees.
• Continued reliance on equity-based compensation could lead to an increase in the outstanding share count over time.

Future Outlook

N/A. This document reports a past insider transaction and does not provide forward-looking statements or guidance.

Industry Context

This Form 4 filing details a specific insider compensation event for BioSig Technologies, Inc. It does not provide broader industry trends or competitive analysis. Equity grants to directors and significant shareholders are a common practice across industries to align interests and compensate for services.

Comparison to Industry Standards

• Equity grants as compensation are a standard practice in publicly traded companies, particularly in the biotechnology and medical device sectors where BioSig Technologies operates.
• While specific comparable companies or projects are not mentioned in this filing, the use of an equity incentive plan for compensation is consistent with general corporate governance practices.
• The size of the grant (900,000 shares) and its valuation ($5.05 per share) would need to be assessed against peer compensation structures and company performance, which is beyond the scope of this specific Form 4.

Corporate Governance

Related Party Transactions

• The grant of 900,000 shares to Anthony N. Amato, a Director and 10% Owner, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new shares, but also increased alignment of a significant insider's interests with shareholder value.
• Management/Director: Anthony N. Amato received significant equity compensation for services, increasing his stake and aligning his financial interests with the company's performance.
• Company: Conserves cash by using equity compensation instead of cash for services.

Key Dates

Keywords

BioSig Technologies, BSGM, Form 4, insider transaction, stock grant, equity compensation, beneficial ownership, Anthony Amato, director, 10% owner